📅 PUBMED DAILY TRIAGE — 2026-06-02

Window: 2026-06-01T09:00:00Z → 2026-06-02T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~89 candidates | Classified: 22 High priority: 6 | Standard: 11 | Low/archive: 5 | Unsolicited finds: 0 Run status: ✅ SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

T1 — Hematologic Malignancies

TR-2026-06-02-001 · PMID 42225613 · Dual epitope anti-LILRB4 STAR-T-cell therapy for R/R AML · 9/10 🟠 NOVEL_TREATMENT

First-in-human Phase 1 trial (NCT05548088) of a nanobody-based STAR-T cell product targeting LILRB4 — a monocytic AML-specific surface receptor — achieved 50% ORR (3/6 evaluable) with zero ICANS and zero grade ≥3 CRS; scRNA-seq pinpoints monocyte suppression as the primary resistance mechanism. Signal Transduct Target Ther. Published in STTTT 2026-06-01.

T3 — Early Cancer Detection (Liquid Biopsy / ctDNA / cfDNA)

TR-2026-06-02-004 · PMID 42225236 · CIRCULATE trial: ctDNA-guided adjuvant chemo in stage II colon cancer (AIO/ABCSG RCT) · 8/10 🔴 EARLY_CANCER_DETECTION

ctDNA positivity (2.9% of screened patients) carries a 4.28-fold worse 3-year DFS hazard ratio vs ctDNA-negative; per-protocol analysis shows adjuvant CHEMO reduces recurrence from 62% to 19% (HR 0.23, P=0.009) in ctDNA-positive patients — the strongest prospective RCT signal yet for ctDNA-guided adjuvant decision-making in stage II CRC. Annals of Oncology (ITT endpoint not met; n=26 CHEMO arm; trial ended early due to funding).

TR-2026-06-02-005 · PMID 42222887 · cfDNA epigenetic biomarkers for ALS diagnosis and progression · 8/10 🔴 EARLY_CANCER_DETECTION

Multimodal cfDNA methylation analysis achieves AUC 0.91 (±0.10) for ALS diagnosis with 70% sensitivity at ~100% specificity — far exceeding any existing blood-based ALS diagnostic — and methylation signatures correlate with disease progression markers. JCI 2026. n=61 (requires large-scale validation). First cfDNA liquid biopsy approach for ALS.

T6 — Novel Therapeutics

TR-2026-06-02-002 · PMID 42225988 · ABBV-706 (SEZ6-targeting ADC) Phase 1 in R/R SCLC — ORR 52%, mOS 12.4 months · 9/10 🟠 NOVEL_TREATMENT

In the largest Phase 1 SCLC cohort (n=124 R/R SCLC monotherapy), ABBV-706 achieved a 52% ORR with median OS 12.4 months at the RP2D 1.8 mg/kg Q3W — dramatically exceeding historical salvage benchmarks (~10-15% ORR, ~6 months OS) for relapsed SCLC. Nature Medicine. Novel SEZ6 target expressed on SCLC/neuroendocrine neoplasms; linker is Top1i. (NCT05599984)

T8 — Aging, Longevity & Population Health

TR-2026-06-02-006 · PMID 42223825 · Single-nucleus profiling reveals BBB senescence unit driving AD pathology · 8/10 ⚪ PROMISING_PRELIMINARY

snRNA-seq integration of 75 human brain samples reveals a coordinated 4-cell-type BBB senescence unit (astrocytes, pericytes, microglia, T cells) in Alzheimer's disease driven by SPP1-CD44 intercellular signaling; SPP1 validated as hub gene in CSF proteomics from AD patients — an immediately testable therapeutic target. Mol Neurobiol 2026. (Alert suppressed — 5-alert cap reached; 6th HIGH article)

T9 — Rare Diseases

TR-2026-06-02-003 · PMID 42224366 · RAASi exacerbates anemia in sickle cell disease (Blood 2026) · 8/10 🟢 NEAR_TERM_IMPLEMENTABLE

Multi-cohort study (n=658 cross-sectional + two longitudinal cohorts + SCD mouse model) demonstrates RAASi drugs — currently standard-of-care for SCD nephropathy — reduce hemoglobin by ~0.5 g/dL in SCD patients via impaired erythropoiesis, not EPO reduction. Direct and immediate clinical implication: monitor Hgb closely in SCD patients on RAASi. Published in Blood.

🟢⚪ STANDARD (4–7) — Top by Topic

T1 — Hematologic Malignancies

• PMID 42225967 · TP53-deficient AML secretome suppresses T-cell engager (BiTE/AMG330) efficacy via TGF-β1 · 7/10 · Leukemia 2026
• PMID 42225953 · RFX7 suppresses Myc-driven lymphomagenesis in B cells · 7/10 · Nature Immunology 2026
• PMID 42225671 · ATL nationwide registry (n=638): lymphocyte counts independently prognostic · 7/10 · Blood Cancer J 2026
• PMID 42225588 · ADCs in hematologic malignancies [review: GO, InO, brentuximab, polatuzumab, belantamab] · 5/10 · Cancer Suppl 2026

T2 — CBC-Based ML in Hematology

• PMID 42220235 ⭐ · ThalP hybrid ML model for thalassemia classification using CBC (accuracy 83.1%, n=349 external validation) · 6/10 · Technol Health Care 2026 · T2 FIRST RESULT IN 4 CONSECUTIVE RUNS

T3 — Early Cancer Detection

• PMID 42225541 · ctDNA dilution phenomenon in mCRC monitoring: absolute ctDNA can rise while tumor fraction falls · 5/10 · Clin Colorectal Cancer 2026

T4 — AI/ML in Clinical Diagnostics & Imaging

• PMID 42226010 · Computer vision model (AUROC 0.852) detects inflammatory arthritis from smartphone photos in Indian rheumatology clinics · 7/10 · Rheumatology 2026
• PMID 42225843 · Deep learning for acute ischemic stroke on non-contrast CT; AI-assisted +3.6% accuracy vs unaided (n=917, multi-reader) · 7/10 · Sci Rep 2026

T5 — Precision Oncology / Genomics

No HIGH-priority articles this run. Top candidates were reviews or broad biomarker studies scoring ≤4. T5 query continues to yield high volume (208 results) but low-signal top hits; query refinement recommended.

T6 — Novel Therapeutics

• PMID 42226008 · KRAS-driven immune exclusion in PDAC: mechanisms (autophagy MHC-I, myeloid suppression) and reversal strategies · 5/10 · Oncologist 2026
• PMID 42226005 · KRAS G12R in PDAC: structural barriers to current inhibitors; pan-RAS(ON) ternary inhibitors emerging · 5/10 · Oncologist 2026
• PMID 42225999 · ADCs in breast cancer [review] · 4/10 · Cancer Suppl 2026
• PMID 42226003 · ADCs in SCLC [review: DLL3, SEZ6, TROP2 targets] · 4/10 · Cancer Suppl 2026
• PMID 42226019 · ICI adverse events and HRQoL in HNSCC: scoping review (98 studies) · 4/10 · Head Neck 2026

T7 — Cardiovascular-Metabolic

• PMID 42225305 · Oral semaglutide 25mg vs orforglipron 36mg: ITC shows -3.2% weight loss advantage for semaglutide · 6/10 · Diabetes Obes Metab 2026 (Novo Nordisk sponsored; interpret cautiously)
• PMID 42225676 · Cardiometabolic multimorbidity 14.43% in Iran (n=16,453, WHO STEPS 2021); COVID-19 hospitalization as novel determinant · 5/10 · Sci Rep 2026

T8 — Aging, Longevity & Population Health

• PMID 42222892 · cGAS-STING signaling in neuroinflammation and brain aging [JCI review; pharmacological inhibitors catalogued] · 4/10 · JCI 2026
• PMID 42222939 · Dementia landscape in India (prevalence, risk factors, gaps) · 4/10 · Alzheimers Dement 2026

T9 — Rare Diseases

• PMID 42224345 · [211At]-CD45 RIT conditioning for autologous HSPC gene therapy in NHPs: no non-hematologic toxicities, 70% gene-editing at 18 months (Blood 2026) · 5/10 (cap: NHP only)
• PMID 42224713 · Gene therapy knowledge/attitudes in AATD community (n=1112): higher knowledge predicts acceptance; prefer dual liver/lung targeting · 4/10 · Chronic Obstr Pulm Dis 2026

💡 UNSOLICITED FINDS

None this run. All sentinel scan hits (912 raw results; top 10 reviewed) duplicated watchlist-topic captures.

📊 TODAY'S BREAKDOWN

By research category:

• Diagnostics: 6 | Treatment Innovation: 8 | Genomics/Precision Medicine: 3 | Early Detection: 2 | Public Health: 3

By evidence maturity:

• Exploratory: 12 | Validated: 8 | Potentially Practice-Changing: 0

By watchlist topic (reviewed / kept / highest score):

By source type: Peer-reviewed: 22 | Preprint: 0

Topics with zero 8+ articles this run: T2 (best 6), T4 (best 7), T5 (best 4), T7 (best 6)

Topics with 8+ articles this run: T1 (1×), T3 (2×), T6 (1×), T8 (1×), T9 (1×) → Total 6 HIGH

🔧 RUN NOTES

• T2 (CBC/ML) streak broken: After 4 consecutive zero-result runs, T2 returned 1 result (PMID 42220235, thalassemia ML classifier, score 6/10). Query refinement from state.json notes confirmed effective.
• PMID 42216561 CLOSED: Third and final consecutive deferral for this Br J Haematol AML article (abstract persistently unavailable from publisher). Classified at title-only, score 2/10 LOW. Will not be deferred in future runs.
• Alert cap: 5 alerts sent (TR-001 through TR-005). PMID 42223825 (BBB Senescence Unit, score 8/10) is the 6th HIGH article — alert suppressed per 5-alert cap. Downstream pipeline should process it from JSON.
• T5 precision oncology: 208 raw results; query too broad. Suggest restricting to ("precision oncology"[tiab] OR "tumor mutational burden"[tiab]) with publication type filters (Clinical Trial OR Validation Study) to reduce noise volume.
• Sentinel scan: Zero unique unsolicited finds. All top sentinel hits were duplicates of watchlist topic captures — a sign that the watchlist coverage is comprehensive for today's publication cohort.
• T8 (Aging) note: T8 produced one HIGH article (mechanistic AD/senescence) but no clinical trial finds. Best performance was molecular-translational this run. cGAS-STING inhibitor data in JCI review is contextually valuable.
• Rolling 7-day note: T7 (Cardiovascular-Metabolic) has not produced a score ≥8 in the past 3 runs; GLP-1/SGLT2 topics return high volume (155 results today) but consistently yield observational or review articles in the top 10. Consider dedicated SGLT2 outcome sub-query OR adjusting retmax to retrieve more candidates.